The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib
Open accessAbstract
Ellison notes that ethical clinical trials should be testing hypotheses based on equipoise; thus, we should expect approximately 50% of trials to support the null hypothesis, whereby a new treatment will not prove to be better than a standard one.We agree completely with this philosophical premise and recognize that a well-designed and well-conducted "null study" is a successful trial.The treatment of diabetic kidney disease would have greatly advanced over the past several decades if 50% of relevant clinical trials had shown efficacy, which unfortunately has not been the case.Within the framework of equipoise, every effort should be made to maximize patient safety, which should always be the paramount concern in study design.The BEACON trial was terminated early because of strong adverse safety signals in study participants who received bardoxolone methyl as compared with those who received placebo.The study did not continue long enough to fully determine the efficacy of the drug for slowing the progression of diabetic kidney disease.We continue to emphasize the need for greater rigor in preclinical testing, careful evaluations of dosing, improved methods for off-target toxicity testing, and biomarker development.We also stress the need for business and regulatory environments that foster innovation.Other authors have also recently called for similar approaches to improving the drug-development process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., de Souza, P., Merchan, J. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303989 · Cited by 1,923
Self-citationMotzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
Self-citation
Cited by
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Hsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.9 · Cited by 2,426
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Self-citationCapitanio, U., & Montorsi, F. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00046-x · Cited by 1,014
Metadata
- Authors
- Motzer, R. J., Hutson, T. E., McCann, L., Deen, K., & Choueiri, T. K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05
- Volume
- 370
- Issue
- 18
- Pages
- 1769-1770
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2316731546
- Cited by
- 271
- References
- 2
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib. https://app.cochat.ai/papers/10.1056/nejmc1400731
- The paper
- Motzer, R. J., Hutson, T. E., McCann, L., Deen, K., & Choueiri, T. K. (2014). Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib. New England Journal of Medicine. https://doi.org/10.1056/nejmc1400731
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.